This guide covers what FDA and EU GMP require for cleaning validation, how acceptance criteria should be established and calculated, what a compliant validation program looks like in practice, and the common gaps that lead to inspection observations.

What cleaning validation is and why it matters

Cleaning validation is the documented evidence that a cleaning procedure reliably removes product residues, cleaning agents, and microbial contamination from manufacturing equipment to a level that does not pose a risk to the next product manufactured in that equipment.

In multi-product pharmaceutical manufacturing, where the same equipment is used to manufacture different products sequentially, the risk is cross-contamination: residues of Product A remaining on the equipment when Product B is manufactured. If those residues are not adequately removed, they may carry over into Product B — potentially causing unexpected pharmacological effects in patients who receive that product and were not prescribed Product A.

The FDA requires cleaning validation under 21 CFR Part 211.67, which states that equipment and utensils shall be cleaned, maintained, and sanitized at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product. The EU GMP requirement appears in Annex 15, which requires cleaning validation with documented procedures, acceptance criteria, and analytical methods.

Setting acceptance criteria: the MACO approach

The central scientific question in cleaning validation is: how much residue is acceptable? The answer requires calculating the Maximum Allowable Carryover (MACO) — the maximum amount of Product A residue that can remain on shared equipment surfaces without posing a risk to patients receiving Product B.

There are two main approaches to MACO calculation:

Health-Based Exposure Limits (HBEL): the current standard

The current regulatory standard, reflected in both FDA and EU GMP guidance, is to base MACO calculations on Health-Based Exposure Limits (HBELs) — specifically the Acceptable Daily Exposure (ADE) or Permitted Daily Exposure (PDE) for each product. The ADE/PDE is a toxicologically derived threshold: the daily dose below which there is no expectation of adverse effects even with lifetime exposure.

As the APIC guidance on cleaning validation states, acceptance criteria should preferably be based on ADE or PDE calculations. This approach is more scientifically defensible than historical dose-based methods because it accounts for the specific toxicological profile of each substance — including highly potent compounds, genotoxic impurities, and biologics, where the older dose-based calculations may produce limits that are either too stringent or not protective enough.

MACO using HBEL is calculated as:

MACO = ADE × Minimum Batch Size of Next Product / Maximum Daily Dose of Next Product

This MACO value is then divided by the shared surface area to derive the surface acceptance criterion in micrograms per unit area (typically μg/cm²).

Historical dose-based criteria

Before the HBEL approach became standard, MACO was commonly calculated using dose-based criteria — typically a 1/1000th of the minimum daily therapeutic dose of Product A in the maximum daily dose of Product B, or a limit of 10 ppm in the product. While some companies retain these criteria for certain product classes, EU GMP and FDA expectations have shifted toward HBEL-based limits as the scientifically justified default.

Facilities still using dose-based criteria should assess whether they can justify those criteria against the HBELs for their products. For highly potent compounds, oncology products, hormones, or biologics, dose-based criteria may not be adequate.

Sampling methods: swab vs. rinse

Cleaning validation uses two primary sampling methods to collect evidence that equipment surfaces have been adequately cleaned:

Swab sampling

Swab sampling involves physically wiping a defined surface area with a pre-wetted swab and then extracting and analyzing the swab for residue. Swabbing is the preferred method for most surfaces because it directly samples the equipment surface at the specific location of interest — particularly hard-to-clean areas like gaskets, joints, ports, and other geometrically complex locations.

Swab sampling requires validation of the swabbing procedure itself: the recovery efficiency of the swab from each surface material must be determined, because not all residue on a surface transfers to the swab with 100% efficiency. Recovery factors below 70% typically require justification.

Rinse sampling

Rinse sampling collects a final rinse solution from inside the equipment after cleaning is complete and analyzes it for residue. Rinse sampling is useful for equipment with complex internal geometries where direct swabbing is not practical, but it has a limitation: it provides an average contamination level across the entire rinsed surface area, and it cannot confirm cleanliness of specific hard-to-clean locations.

Most cleaning validation programs use a combination of swab and rinse sampling — swabs for worst-case locations and rinse for confirmation of overall equipment cleanliness.

Analytical methods for cleaning validation

The analytical method used to measure residue in swab or rinse samples must be validated for sensitivity, specificity, linearity, precision, and recovery. The method must be capable of detecting residues at or below the acceptance limit — an analytical method that cannot reliably detect residues at the MACO threshold cannot support a valid cleaning validation program.

High-performance liquid chromatography (HPLC) with UV detection or mass spectrometry is the standard for small molecule APIs. Total organic carbon (TOC) analysis is used as a non-specific but highly sensitive method for equipment trains where the API is TOC-accessible. For cleaning agents, specific methods for the agents used must also be validated.

The cleaning validation program structure

A complete cleaning validation program includes several interconnected elements:

Cleaning procedure development and documentation

Cleaning procedures must be documented and qualified before validation begins. The procedure specifies cleaning agents, concentrations, temperatures, contact times, sequence of operations, and the equipment and tools used. Variations in any of these parameters can affect cleaning effectiveness, so the validated procedure must be followed exactly in commercial manufacturing.

Worst-case grouping and product selection

In a multiproduct facility, it is not practical to validate every possible product-to-product sequence. The standard approach is to use a worst-case rationale: identify the most difficult-to-clean product (typically the most insoluble or most potent) and the equipment with the most complex geometry, and validate the cleaning procedure for that worst case. If the cleaning procedure is adequate for the worst case, it is considered adequate for all less-difficult cases in the same equipment train.

Protocol development and execution

Cleaning validation protocols must be approved before execution begins. The protocol defines the specific product residue being measured, the sampling locations and rationale (including worst-case locations), the analytical methods to be used, acceptance criteria with their basis (HBEL or other justified approach), and the number of cleaning validation runs required.

Three consecutive cleaning validation runs meeting acceptance criteria is the standard minimum. The runs must use the validated cleaning procedure and must represent actual commercial manufacturing conditions — not special cleaning conditions used only for validation.

Validation report and ongoing monitoring

After execution, a validation report documents the results and confirms that the cleaning procedure is validated for the product/equipment combination evaluated. The report must address any deviations from the protocol that occurred during execution, with an assessment of their impact on the validation conclusions.

Cleaning validation does not end with the validation report. Continued process verification for cleaning — periodic monitoring of cleaning effectiveness during commercial manufacturing — is expected under the lifecycle approach. Changes to cleaning procedures, manufacturing equipment, cleaning agents, or the product portfolio that shares the equipment must be evaluated through change control for their impact on cleaning validation status.

Common cleaning validation findings in FDA inspections

Several patterns appear repeatedly in FDA FDA Form 483 observations for cleaning validation:

Acceptance criteria based on outdated dose-based calculations rather than HBELs for potent or sensitizing compounds. When a new highly potent product is added to the facility’s manufacturing portfolio without reassessment of cleaning acceptance criteria for shared equipment, existing criteria may no longer be protective.

Failure to revalidate after adding new products to shared equipment trains. Each time a new product is introduced, the worst-case analysis must be reassessed, and if the new product changes the worst case, the cleaning validation program must be updated.

Inadequate sampling of worst-case locations. Validation sampling plans that avoid difficult-to-clean areas like gaskets, pump heads, or dead legs do not provide meaningful evidence of cleaning effectiveness in those locations.

Analytical methods that cannot detect residues at the acceptance limit. An analytical method with a detection limit above the MACO threshold cannot confirm that equipment meets acceptance criteria.

Cleaning validation reports that were never updated after equipment modifications. A cleaning validation performed on equipment before a significant repair or modification may not reflect the current equipment configuration.

EU GMP Annex 15 and cleaning validation documentation

EU GMP Annex 15 on qualification and validation requires that cleaning validation studies are documented with a protocol, execution records, and a report. The report must include a summary of results, the acceptance criteria, and a clear conclusion on the validated state of the cleaning procedure.

For products with specific toxicological concerns — highly potent APIs, mutagenic impurities, biologics — EU GMP expectations have aligned with the HBEL-based approach, with authorities expecting that ADE/PDE values have been derived by a qualified toxicologist and used as the basis for cleaning acceptance criteria.

How a QMS platform supports cleaning validation management

Managing cleaning validation documentation — protocols, execution records, analytical data, deviation reports, and ongoing monitoring — across a multiproduct facility requires document control, audit trail, and change control capabilities that connect cleaning validation status to the change management process for the facility.

Cloudtheapp’s QMS platform provides 60+ applications covering document control with version history, change management with impact assessment, Deviation CAPA tracking, and the electronic records infrastructure required under 21 CFR Part 11. When a cleaning procedure or equipment change occurs, the change management workflow in the platform can automatically flag associated cleaning validation documents for review — closing the loop between change control and validation status that manual systems frequently miss.

To see how Cloudtheapp supports pharmaceutical validation programs, request a demo.

Summary

Cleaning validation is one of the most consistently cited areas in pharmaceutical GMP inspections, and the gap between what is required and what many facilities actually maintain is often straightforward: outdated acceptance criteria, incomplete sampling plans, inadequate analytical method sensitivity, or failure to revalidate after equipment or product changes.

A cleaning validation program built on HBEL-based acceptance criteria, validated analytical methods capable of detecting residues at the acceptance limit, and a change control process that triggers reassessment when relevant changes occur will withstand inspection scrutiny. The science is not new — the gap is usually in the quality system infrastructure that keeps the validation current over time.

This post created by and appeared first on Cloudtheapp